^
    Back
    Association details:
    Biomarker:DNMT3A mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:PD-L1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    DNMT3A mutation to identify a subset of non-small cell lung cancers with increased sensitivity to PD-(L)1 blockade.

    Published date:
    05/19/2021
    Excerpt:
    Among 600 NSCLCs, we identified deleterious mutations in the DNA methyltransferase 3A (DNMT3A) gene as the most significant alteration enriched in responders versus non-responders to PD-(L)1 blockade (q-Value < 0.05)….DNMT3A loss was associated with significantly higher objective response rate (ORR, 50% vs 20.5%, P < 0.001), longer median progression-free (mPFS, 9.2 vs 2.9 months, HR 0.60, P < 0.01) and overall survival
    DOI:
    10.1200/JCO.2021.39.15_suppl.9113